DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
SGN-30 is an investigational drug.
There have been 73 clinical trials for SGN-30. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Hodgkin Disease. The leading clinical trial sponsors are Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc., and Genentech, Inc.
Recent Clinical Trials for SGN-30
|A Study of SGN-B6A in Advanced Solid Tumors||Seattle Genetics, Inc.||Phase 1|
|A Safety Study of SGN-TGT in Patients With Advanced Cancer||Seattle Genetics, Inc.||Phase 1|
|A Study of SGN-CD228A in Advanced Solid Tumors||Seattle Genetics, Inc.||Phase 1|